Evaluation of innovative concepts for semi-active and active rotorcraft control

Lead-lag dampers are present in most rotor systems to provide the desired level of damping for all flight conditions. These dampers are critical components of the rotor system, and the performance of semi-active Coulomb-friction-based lead-lag dampers is examined for the UH-60 aircraft. The concept of adaptive damping, or “damping on demand,” is discussed for both ground resonance and forward flight. The concept of selective damping is also assessed, and shown to face many challenges. In rotorcraft flight dynamics, optimized warping twist change is a potentially enabling technology to improve overall rotorcraft performance. Research efforts in recent years have led to the application of active materials for rotorcraft blade actuation. An innovative concept is proposed wherein the typically closed section blade is cut open to create a torsionally compliant structure that acts as its own amplification device; deformation of the blade is dynamically controlled by out-of-plane warping. Full-blade warping is shown to have the potential for great design flexibility. Recent advances in rotorcraft blade design have also focused on variable-camber airfoils, particularly concepts involving “truss-core” configurations. One promising concept is the use of hexagonal chiral lattice structures in continuously deformable helicopter blades. The static behavior of passive and active chiral networks using piezoelectric actuation strategies is investigated, including under typical aerodynamic load levels. The analysis is then extended to the dynamic response of active chiral networks in unsteady aerodynamic environments.PhDCommittee Chair: Bauchau Olivier; Committee Co-Chair: Ruzzene Massimo; Committee Member: Costello Mark; Committee Member: Hodges Dewey; Committee Member: Ozbay Serka

Les elements raisonnes de la religion. Apologetique fondamentale appropriee aux cours superieurs d'humanites et de philosophie.

OPLADEN-RUG0

Description of the First Leptestheria Species (Branchipoda, Spinicaudata) from Brazil

International audienceLeptestheria (Spinicaudata: Leptestheriidae) was collected for the first time from Brazil. This species was found during a study on temporary pools in the municipality of Palmas de Monte Alto in Bahia state, which is in the Caatinga climatic zone. A morphological description of this new species is presented and compared with other known South American species. Our new species differs from the other described species by the form of the head and the telson. The associated fauna is comparable to what was observed by Gurney in 1931 in Paraguay or by Roessler in 1995 in Colombia, indicating possible connections between the dry regions of South America

Description of the First Leptestheria Species (Branchipoda, Spinicaudata) from Brazil

International audienceLeptestheria (Spinicaudata: Leptestheriidae) was collected for the first time from Brazil. This species was found during a study on temporary pools in the municipality of Palmas de Monte Alto in Bahia state, which is in the Caatinga climatic zone. A morphological description of this new species is presented and compared with other known South American species. Our new species differs from the other described species by the form of the head and the telson. The associated fauna is comparable to what was observed by Gurney in 1931 in Paraguay or by Roessler in 1995 in Colombia, indicating possible connections between the dry regions of South America

Impact de l'émergence de la pharmacogénomique sur l'entreprise pharmaceutique

Le secteur pharmaceutique a connu, au cours des dernières années, de nombreux bouleversements autant en interne (baisse de la productivité de sa R&D et l'augmentation des couts de la R&D), qu'environnementaux (la concurrence des génériques, un durcissement des réglementations, une politique publique de réduction des couts et la perte des brevets de nombreux blockbusters) ou encore technologiques (biotechnologies). En parallèle, une tendance se dessine, celle d'un système de santé centré sur le patient avec une personnalisation des traitements (le bon traitement avec la bonne dose pour le bon patient). L'outil le plus prometteur dans ce domaine est la médecine génomique. Bien qu'il semble évident que cette innovation soit profitable au patient, on peut se demander si l'industrie pharmaceutique la développera, car un meilleur ciblage du patient a également pour conséquence la réduction de la taille du marché et donc une diminution du chiffre d'affaires. Mais d'autres facteurs rentrent en jeux dans l'analyse de la rentabilité du médicament tel qu'une possible amélioration de la productivité de la R&D.TOULOUSE3-BU Santé-Centrale (315552105) / SudocSudocFranceF